Bohan Li

Supplementary Table S6 shows the sequences of shRNAs used in this study.

Supplementary Table S3 shows UCSC-predicted transcription factors that bind to CKB promoters.

Supplementary Table S1 shows PCr IHC staining score in human glioma microarray.

Supplementary Table S4 shows PCr and BRD2 IHC staining scores in the serial sections of human glioma microarrays.

Supplementary Figures S1 shows that GSCs produce high levels of phosphocreatine through upregulating CKB. Supplementary Figures S2 shows that ZEB1 promotes CKB transcription in GSCs. Supplementary Figures S3 shows that knockdown of CKB impedes GBM growth. Supplementary Figures S4 shows that disruption of phosphocreatine production impedes GBM growth. Supplementary Figures S5 shows that cCr treatment shows no side effect on mice. Supplementary Figures S6 shows that phosphocreatine binds to BRD2 and inhibits its ubiquitin mediated proteasomal degradation. Supplementary Figures S7 shows that phosphocreatine promotes chromosome segregation and GSC proliferation through BRD2 mediated transcription. Supplementary Figures S8 shows that disruption of phosphocreatine biosynthesis by cCr improves JQ1 therapeutic efficacy in GBM.

Supplementary Table S5 shows the detailed genetic mutations of four GBM cell lines.

Supplementary Table S2 shows CKB IHC staining score in human glioma microarray.

Supplementary Table S7 shows the primer sequences used for Real-Time PCR.

Supplementary Table S2 shows CKB IHC staining score in human glioma microarray.

Supplementary Table S6 shows the sequences of shRNAs used in this study.